Related Experiment Video
Updated: Feb 3, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
In silico identification and in vitro validation of nogalamycin N-oxide (NSC116555) as a potent anticancer compound
Phongphat Obounchoey1, Lueacha Tabtimmai2, Praphasri Suphakun2
1Interdisciplinary Program in Genetic Engineering, Graduate School, Kasetsart University, Chatuchak, Bangkok, Thailand.
Abstract:
The epidermal growth factor receptor (EGFR) was found to be overexpressed in several cancers, especially in lung cancers. Finding new effective drug against EGFR is the key to cancer treatment. In this study, the GOLD docking algorithm was used to virtually screen for novel human EGFR inhibitors from the NCI database. Thirty-four hit compounds were tested for EGFR-tyrosine kinase (TK) inhibition. Two potent compounds, 1-amino-4-(4-[4-amino-2-sulfophenyl]anilino)-9,10-dioxoanthracene-2-sulfonic acid (NSC125910), and nogalamycin N-oxide (NSC116555) were identified with IC50 values against EGFR-TK comparable to gefitinib; 16.14 and 37.71 nM, respectively. However, only NSC116555 demonstrated cytotoxic effects against non-small-cell lung cancer, A549, shown in the cell cytotoxicity assay with an IC50 of 0.19 + 0.01 µM, which was more potent than gefitinib. Furthermore, NSC116555 showed cytotoxicity against A549 via apoptosis in a dose-dependent manner.
Insights
Researchers screened for new epidermal growth factor receptor (EGFR) inhibitors using computational methods. One compound, NSC116555, showed potent anti-cancer activity against lung cancer cells, inducing apoptosis.
Area of Science:
- Oncology
- Pharmacology
- Computational Chemistry
Background:
- Epidermal growth factor receptor (EGFR) overexpression is common in various cancers, particularly lung cancer.
- Developing effective EGFR inhibitors is crucial for cancer therapy.
Purpose of the Study:
- To virtually screen for novel human EGFR inhibitors.
- To identify potent compounds with therapeutic potential against EGFR-driven cancers.
Main Methods:
- Utilized the GOLD docking algorithm for virtual screening of the NCI database.
- Tested 34 hit compounds for EGFR-tyrosine kinase (TK) inhibition.
- Performed cell cytotoxicity assays on non-small-cell lung cancer (A549) cell line.
Main Results:
- Identified two potent EGFR-TK inhibitors: NSC125910 (IC50 = 16.14 nM) and NSC116555 (IC50 = 37.71 nM).
- NSC116555 exhibited significant cytotoxicity against A549 cells (IC50 = 0.19 µM), surpassing gefitinib's potency.
- NSC116555 induced apoptosis in A549 cells in a dose-dependent manner.
Conclusions:
- NSC116555 is a promising novel inhibitor of EGFR-TK with demonstrated cytotoxic and apoptosis-inducing effects against non-small-cell lung cancer.
- This study highlights the potential of computational screening in discovering new anti-cancer drug candidates.
Related Concept Videos
Oxidation Numbers
Reliability and Validity
Oxidation-Reduction Reactions
Coordination Compounds and Nomenclature
Cancer Cell Migration through Invadopodia
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

